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A B S T R A C T
Our aim is to provide review of available studies on Langerhans cell histiocytosis (LCH) and discuss treatment for
polyostotic monosystem form of disease based on our clinical experience. LCH is an enigmatic disease with insufficiently
understood etiology, pathophysiology, and variety of clinical presentations ranging from solitary eosinophilic granu-
loma to severe multisystem disease. It is marked by formation of granuloma in practically any organ. We present rare
case of multifocal bone disease in 36-year old patient without visceral involvement. Treatment protocols for adult LCH
patients, especially for uncommon form in our case have not yet been defined. Our therapeutical trial with corticosteroids
showed limited success with numerous side-effects. We conclude that LCH treatment can commence only after diagnosis
and staging of the disease. Other factors like patient’s age, comorbidity, general condition, severity of symptoms and con-
traindications for therapy modalities should also be considered. In our experience expectative approach has better clini-
cal outcome than immunosuppressive therapy in patients suffering from polyostotic multifocal form LCH with mild
symptoms.
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Introduction
Langerhans cell histiocytosis is a rare disease with
mostly unexplained etiology and pathophysiology charac-
terized by pathological accumulation of Langerhans cells
in various body organs. Recent findings classify it as a
histiocytosis – a group of proliferative disorders of mono-
cyte-macrophage system cells. Other members of this
group are insufficiently understood macrophage disor-
ders: hemophagocytic lymphohistiocytosis, Castleman
and Rosai-Dorfman disease1. Langerhans cell histiocyto-
sis (LCH) is traditionally divided into three clinical enti-
ties: Abt-Letterer-Siwe disease (fulminant disseminated
form, predominant in children under age 2), Hand-Schü-
ller-Christian disease (chronic disseminated form with
involment of bone and internal organs) and eosinophilic
granuloma (chronic localized bone disease)2. Practically
every organ can be involved. Significant overlapping has
been observed studying three disease presentations men-
tioned above. For instance, patient presenting with so-
litary eosinophilic granuloma can gradually evolve into
multisystem form involving internal organs. Therefore
new classification was developed with much greater em-
phasis on treatment and prognosis of LCH dividing it
into monosystem and multisystem form. Monosystem
form is further subdivided into unifocal and multifocal
(monostotic and polyostitic in case of bone affection)3.
First records of LCH date from 1893 when 3-year old
boy with diabetes insipidus, exophtalmus, hepatospleno-
megaly, bronze dry skin and petechiae was described2.
Lichtenstein recognized these three seemingly separated
clinical entities as parts of unique disease and named it
histiocytosis X (X stands for unknown cause)1. In 1973 it
was discovered that Langerhans cells are responsible for
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histiocytosis X. Langerhans cell histiocytosis has been
the most frequently name used in medical terminology
since then4.
Epidemiological data on LCH are very sparse due to
low incidence and the fact that clinicians rarely consider
it as a differential diagnosis. More than 50% of described
cases affect children. We still lack sufficient data on adult
patients; incidence is estimated by some authors as 1 to 2
cases per million with most patients presenting with
multisystem form of disease (69%). Median of incidence
in children with monosystem form is between 5 and 15,
and 2 years for multisystem form of disease5. Pulmonary
LCH is more prevalent among smokers, therefore many
cases of remission have been described after quitting1,4.
There is a slight predominance among male patients in
osseus disease, but all other forms are more prevalent
among women5,6.
Etiology is also mostly unknown. There are two con-
fronted theories. Some authors explain cell proliferation
as a malignant neoplastic process supported by finding of
monoclonal Langerhans cells in lesions. Another group
considers proliferation as an augmented immune system
response to enviromental antigens which are yet to be
identified. Finding of Glotzebecker et al. identified hu-
man herpes virus type 6 (HHV6) in 71% of examined
eosinophilic granulomas. This makes HHV6 a possible
pathogen4. Diniz et al. described eosinophilic granuloma
as an inflammatory reaction to periapical tooth infection
which lends support to the theory of LCH as a cytokine
network malfunction disorder. Smoking is widely ac-
cepted as a risk factor for pulmonary LCH1,4. Hereditary
factors might be involved because 1% of patients re-
ported positive family history and identical twins show
86% concordance1. Etiology is yet to be clarified but it is
most probably a consequence of innate immune system
predisposition to react to some enviromental antigen
with an abnormal proliferation of Langerhans cells.
Pathological finding is uniform regardless of disease
manifestation. Lesions comprise of activated Langerhans
cells surrounded by interdigitating cells, macrophages, T
lymphocytes, multinuclear histiocytes and eosinophils.
Besides characteristic morphology, Langerhans cells are
further identified histochemically by the presence of
Cd1a and S-100 surface markers and electromicroscopi-
cally by the presence of Birbeck granules1,2. Above men-
tioned pathological findings are obligatory for diagnosis.
Clinical presentation is extremely diverse since LCH
can involve virtually any organ leading to the delay in
correct diagnosis of approximately 4 months. Most of the
clinical data have been acquired among children, with
only few studies describing disease in adults4. LCH is
more likely to occur in tissues with abundant reticu-
loendothelial system. Bones are affected in 70% of pa-
tients, predominantly skull, pelvis, proximal femur, ribs
and mandibule (common disease localization in adult pa-
tients)2. Rarely, eosinophilic granulomas can be found in
vertebrae. Most clinical reports found solitary bone le-
sions, but affected bones can be a part of multisystem
disease. Reports on polyostotic monosystem LCH with-
out visceral involment are very sparse, mostly as case re-
ports or minor group of patients in retrospective studies.
Some bone lesions are asymptomatic, others present
with localized pain in 90% of affected patients. Chronic
otitis media, sinusitis, mastoiditis and pathological frac-
tures have also been described. Cranial base involment
can cause diabetes insipidus, the most common endo-
crinopathy in LCH patients. 20% of pediatric cases of dia-
betes insipidus are caused by histiocytosis with increas-
ing incidence in adult population. Other organs can be
involved solitary or as a part of multisystem disease.
Granulomas can be found in liver, spleen, bone marrow
(associated with unfavorable prognosis), central nervous
system, digestive tract (causing malapsorption in chil-
dren), skin (seborrheic intertriginous exanthema) and
lymph nodes. Peculiar site is a female genital tract be-
cause lesions can mimic some sexually transmitted disea-
ses1,6. Pulmonary LCH is commonly decribed as a sepa-
rate entity causing interstitial lung disease which can
lead to irreversible pulmonary fibrosis4. Multisystem
form of LCH can begin insidiously with general symp-
toms such as low grade fever, malaise, myalgia and the
loss of appetite. Clinical presentation is more acute in
younger patients. The most fulminant disease form oc-
curs in children under age 2, sometimes with lethal out-
come.
After establishing clinical indication, diagnosis is de-
termined by imaging techniques and confirmed patho-
histologically by finding of atypical Cda1+ and S100+
Langerhans cells with Birbeck granules1. Conventional
radiograph can diagnose most lesion as osteolytic areas
surrounded by reactive sclerosis which can also be found
in numerous malignant bone conditions, e.g. osteosarco-
ma2. Spread of the disease is estimated by bone radio-
nuclide scan and positronic emission tomography (PET)
while computed tomography (CT) and magnetic reso-
nance imaging (MRI) assess granuloma relation to sur-
rounding anatomical structures. High resolution CT
(HRCT) is a preffered test for the assessment of pulmo-
nary LCH and MR is more convenient to show soft tissue
involment (especially brain). Laboratory investigations
in every patient should include complete blood count,
blood urea nitrogen, electrolytes, liver and renal function
tests, erythrocyte sedimentation rate, alkaline phospha-
tase, serum and urine osmolality.
Differential diagnosis is extensive and depends on
clinical form of LCH and patient’s age. In adult patients
with bone involment it should include bone metastases,
plasmocytoma, primary bone tumors, fibrous dysplasia
and ameloblastoma7.
Case Report
36-year old male came to his physician and was com-
plaining of right hip pain, headache, tinnitus and hearing
loss in his right ear. Family history was unremarkable. In
childhood he had suffered from bilateral congenital hip
dysplasia. He was previously diagnosed with psoriasis
vulgaris. The patient smokes one pack of cigarettes a day
while the rest of history is unremarkable. During work-
up for tinnitus multiple lytic areas on calvaria cranii
were spotted using craniogram (Figures 1a and b). Since
MRI of head showed them as multiple soft tissue forma-










tions, clinical suspicion of LCH was established. Further
imaging (CT of the head) located one of those lesions on
tip of the pyramid pressuring vestibulocochlear nerve
and thus explaining patinent’s audiological symptoms.
Frontal bone biopsy confirmed the diagnosis of eosi-
nophilic granuloma. Further radiological and laboratory
workup (ultrasound of abdomen, lymph nodes and heart,
chest and bone X-rays, bone marrow biopsy) determined
spread of disease. Multiple bone granulomas (on hu-
merus, scapula, ribs, skull, proximal femur and pelvis)
were identified without any internal organs involved.
Bone marrow biopsy excluded malignant proliferation.
Due to intensive pain and patient’s history of hip dys-
plasia additional pelvic CT was ordered showing signifi-
cant hip destruction caused by eosinophilic granulomas
combined with consequences of delayed treatment of hip
dysplasia.
Current symptoms and possibility of disease progres-
sion compeled us to start a treatment with metilpre-
dnizolon 1 mg/kg/day, gradually reducing dosage com-
bined with prophylactic bisphosphonate treatment. After
7 months of treatment there was no improvement in pa-
tient’s condition and PET-CT of affected regions indi-
cated neither disease progression nor regression (Figures
2a and b). However, patient developed characteristic
corticosteroid therapy adverse effects: cushingoid ap-
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Fig. 1. a) Craniogram (lateral projection) showing multiple lytic areas in frontal, parietal and temporal bones marked by arrows.
b) Anteroposterior projection.
Fig. 2. a) PET-CT showing persistent confluenting lesions of calvariae cranii after 7 months of corticosteroid therapy (arrows).









pearance and diabetes mellitus. Repaglinid was proscri-
bed with unsatisfying result in controlling glycaemia.
Therefore it was soon replaced by roziglitazon. During
rutine checkup patient complained of calf swelling. Re-
peated workup excluded organ infiltration that would ex-
plain oedema (heart and kidneys). Afterwards we found
that patient took significant amount of over-the-counter
non-steroidal anti-inflammatory drugs which (combined
with roziglitazon) caused fluid retention and oedema.
Oedema withdrew after removing these drugs from ther-
apy. Corticosteroids were abandoned and bisphoshonates
were continued. Patient was ordered on often chekups
and reffered to orthopedic surgeon to consider hip re-
placement surgery. He was also encouraged to abstine
from smoking.
Discussion
Decision about treatment is made after final diagno-
sis and disease staging (monosystem or multisystem). We
are confronted with two difficult doubts: should adult pa-
tients with mild to moderate symptoms receive any sys-
temic treatment in paucity of clinical guidelines on con-
ducting that treatment. Many cases of spontaneous disea-
se remission have been described (even in multisystem
form) contributing to unpredictability of LCH clinical
course1. Most authors agree that expectative approach
can be applied in patients with solitary eosinophilic gra-
nulomas if they cause no pain, deformity or loss of func-
tion.
Otherwise there are multiple treatment modalities:
solitary, easily accessible lesions can be surgically extir-
pated, intralesional corticosteroid application and radio-
therapy are also possible1,2,6. Although clinical guidelines
are still under development, chemotherapy is widely
used in treating multisystem form of LCH6. Two clinical
studies exist for children8,9 and there are two more under
way. First randomized controlled study in adult patients
started in 2004. First of the above mentioned studies
showed similar outcomes in children treated with vinbla-
stin or etoposide, with higher rate of etoposide toxicity8.
Second study showed better results combining etoposide
or vinblastin with prednisone. Ongoing adult patients
study implements 6 or 12 month protocol of combined
vinblastin and predisone treatment with addition of 6-mer-
captopurine. Former protocol is used to treat polyostotic
monosystem disease and granulomas in high-risk loca-
tions (e.g.anterior and middle cranial fossa) due to po-
sibility of spread to the brain and high relaps rate if
treated with monotherapy. Complete remission in those
patients was usually achieved after second cycle of treat-
ment6.
Some children with chemotherapy resistant multisys-
tem form of disease benefit from alogenic bone marrow
transplantation10. Most authors concur that corticoste-
roids and smoking cessation are reasonable first line
treatment for pulmonary LCH. Lung transplantation is
also an option for refractory cases1,4.
Disease course and response to therapy are highly un-
predictable. Solitary bone lesions generally have an ex-
cellent prognosis with complete remission in 90% of
cases2. Prognosis of multisystem and polyostotic form of
LCH depends of several factors. Children under age 2
and patients with unfavourable sites (bone marrow, liver,
spleen and lungs) are considered high risk patients1. Re-
sponse to therapy after 6 weeks has recently been identi-
fied as the most important prognostic factor8,9. Involve-
ment of 3 or more bones is associated with unfavorable
prognosis in adults. Complications of LCH are disease
and therapy related. The most frequent are diabetes
insipidus, skeletal deformities, hearing loss and neuro-
logical deficits. Main causes of mortality are development
of chronic cor pulmonale, chemotherapy adverse-effects
and heart failure. Increased incidence of malignant dis-
ease was also observed among LCH patinents6. Rigorous
clinical and radiological follow up is essential because
disease can relapse at any age.
Conclusion
Presented case is interesting in several ways. LCH is
extremly uncommon disease rarely considered in differ-
rential diagnosis. Clinical data on adult patients treat-
ment is sparse bacause all clinical forms of LCH mostly
occur in children. Besides that, multifocal eosinophilic
granulomas disease form is not as frequent as solitary form
and is usually accompanied by visceral manifestation,
which is not the case with our patient. Defining universal
therapy guidelines is troublesome due to low incidence
and insufficient data from clinical studies. Radiotherapy,
surgical extirpation and corticosteroid infiltration were
not the option for our patient due to dissemination and
localization of granulomas. Most studies recommend
chemotherapy only in cases of viceral involvement and
severe symptoms. Additionally, current protocol used in
clinical trial for adult LCH (LCH-A1) is under scrutiny
due to high incidence of vinblastin-induced polyneuro-
pathy. In our experience long-term corticosteroid therapy
results in minor clinical and radiological improvement in
disease natural course, but causes multiple adverse effects,
especially steroid diabetes. Therefore current treatment
without unique guidelines should be strictly individual,
following pathohistological diagnosis and detailed stag-
ing. Patient’s age, general condition, comorbidity, sever-
ity of symptoms and contraindications for some therapy
modalities should also be considered. Only after assess-
ment of above parameters we can decide between ex-
pectative approach with rigorous checkups and active
treatment by means of surgery, radiotherapy, immu-
nomodulation or chemotherapy. Our experience advo-
cates expectative approach in patients with monosystem
polyostotic form of LCH.
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MONOSISTEMSKI MULTIFOKALNI OBLIK HISTIOCITOZE LANGERHANSOVIH STANICA
(VI[ESTRUKI EOZINOFILNI GRANULOMI KOSTIJU) KOD 36-GODI[NJEG BOLESNIKA:
PRIKAZ SLU^AJA, TERAPIJSKE DVOJBE I PRIKAZ LITERATURE
S A @ E T A K
Cilj na{eg istra`ivanja je dati pregled dostupne literature o histiocitozi Langerhansovih stanica (LCH) te razmotriti
lije~enje poliostotskog monosistemskog oblika bolesti na temelju na{eg klini~kog iskustva. LCH je bolest nerazja{njene
etiologije i patofiziologije s heterogenom klini~kom slikom; od solitarnih eozinofilnih granuloma sve do te{kih multi-
sistemskih oblika bolesti. Obilje`ava je stvaranje granuloma sistemski, u organima. Predstavljamo rijedak slu~aj multi-
fokalnog ko{tanog oblika bolesti kod 36-godi{njeg bolesnika bez zahva}anja unutarnjih organa. Protokoli lije~enja LCH
kod odraslih bolesnika, posebno rijetkog oblika u na{em slu~aju jo{ uvijek nisu definirani. Poku{aj lije~enja kortikoste-
roidima nije donio zna~ajno pobolj{anje na {tetu nuspojava. Lije~enje LCH mo`e zapo~eti tek nakon dijagnoze i procje-
ne pro{irenosti bolesti. U obzir treba uzeti i ostale ~imbenike – dob pacijenta, op}e stanje, ostale bolesti te kontrain-
dikacije za pojedine oblike lije~enja. Prema na{em iskustvu kod bolesnika s poliostotskim monosistemskim oblikom
bolesti sa blagim simptomima ekspektativni pristup daje bolje rezultate od imunosupresivnog lije~enja.
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